Pyxis Oncology (PYXS) Cash from Operations (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Cash from Operations of 10427000.0 for Q4 2025, up 45.95% year-over-year from 7144419.07 in Q4 2024, and up 21.47% quarter-over-quarter from 13277000.0 in Q3 2025.
Pyxis Oncology (PYXS) Cash from Operations (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Cash from Operations for 6 consecutive years, with 10427000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 45.95% year-over-year to 10427000.0; the TTM figure through Dec 2025 stood at 63502000.0 (down 10.11% YoY), while the FY2025 annual figure was 63502000.0, down 10.11% from the prior year.
- Cash from Operations climbed to 10427000.0 in Q4 2025 per PYXS's latest filing, from 13277000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2862000.0 in Q2 2021 and bottomed at 27679000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 15827200.0 across 5 years, with a median of 17325000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 928.51% — and 2024, when it soared 72.74%.
- Pyxis Oncology's Cash from Operations stood at 12169000.0 in 2021, then sank by 42.88% to 17387000.0 in 2022, then climbed by 12.27% to 15254000.0 in 2023, then declined by 26.46% to 19290000.0 in 2024, then soared by 45.95% to 10427000.0 in 2025.
- Business Quant data shows PYXS's Cash from Operations at 10427000.0 in Q4 2025, 13277000.0 in Q3 2025, and 17263000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.43 Mn |
| Dec 31, 2025 | -10.43 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Jun 30, 2025 | -17.26 Mn |
| Jun 30, 2025 | -17.26 Mn |
| Mar 31, 2025 | -22.54 Mn |
| Mar 31, 2025 | -22.54 Mn |
| Dec 31, 2024 | -19.29 Mn |
| Dec 31, 2024 | -19.29 Mn |
| Sep 30, 2024 | -14.67 Mn |
| Sep 30, 2024 | -14.67 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -20.71 Mn |
| Mar 31, 2024 | -20.71 Mn |
| Dec 31, 2023 | -15.25 Mn |
| Dec 31, 2023 | -15.25 Mn |
| Sep 30, 2023 | -17.58 Mn |
| Sep 30, 2023 | -17.58 Mn |